Next steps in the evolution of AAV vector characterization technologies

Abstract

<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://bioinsights.blob.core.windows.net/uploads/Eduard_picture copy.jpg" data-image="1"></div><div class="author-det"> <b>Eduard Ayuso</b> is Chief Technology Officer at DiNAQOR (Zürich, Switzerland), a genetic medicine platform company focused on addressing severe inherited cardiac diseases. Dr Ayuso is an expert in the field of gene therapy using viral vector platforms, including adenoviral vectors, helper-dependent adenoviral vectors, and adeno-associated vectors (AAV), as well as their design, manufacture, and purification. With over two decades of academic and industry consulting experience, he has made significant contributions to the field of in vivo gene transfer in small and large animal models of diseases, as well as AAV vector development and analytics. Dr Ayuso previously served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at University of Nantes. Since 2018, he has served as vice president of the French Society for Gene and Cell Therapy. He is also a member of the Translational Science and Drug Product Development committee of the American Society for Gene and Cell Therapy. Dr Ayuso earned his PhD in Biochemistry and Molecular Biology and his degree in Veterinary Medicine from Autonomous University of Barcelona. </div></div></div>